Examkin

Question

Difficulty: HardPharmacologic Interventions

A 7474-year-old female is evaluated in the emergency department for severe shortness of breath, confusion, and lethargy that has progressively worsened over the past 4848 hours. The patient has a known medical history of ischemic cardiomyopathy with a left ventricular ejection fraction of 20%20\%, chronic kidney disease stage 33, and type 22 diabetes mellitus. Her home medications include sacubitril-valsartan, carvedilol, spironolactone, empagliflozin, and aspirin.

Upon arrival, she is difficult to arouse but oriented to person only. Her extremities are cool and mottled, with weak distal pulses and delayed capillary refill. Jugular venous distention is prominent, estimated at 1212 cm H2OH_2O. Auscultation of the lungs reveals diffuse bilateral crackles extending to the apices. Cardiac examination reveals tachycardia with a regular rhythm and a distinct S3S_3 gallop.

Initial vital signs are:
Blood pressure: 78/5278/52 mm Hg
Heart rate: 118118/min
Respiratory rate: 2828/min
Oxygen saturation: 84%84\% on room air

Point-of-care laboratory testing reveals:
Serum creatinine: 3.43.4 mg/dL (baseline 1.61.6 mg/dL)
Serum potassium: 5.45.4 mEq/L
Venous lactate: 5.25.2 mmol/L

The patient is immediately placed on noninvasive positive pressure ventilation. The physician is preparing the initial pharmacologic management plan.

Which of the following interventions are appropriate for this patient at this time? (Select all that apply)

  1. Initiate an intravenous dobutamine infusionAnswer
  2. Discontinue home carvedilol therapyAnswer
  3. Discontinue home sacubitril-valsartan therapyAnswer
  4. D
    Administer a 1,0001,000 mL intravenous normal saline bolus
  5. E
    Initiate an intravenous nitroglycerin infusion
  6. F
    Delay vasoactive therapy until a formal transthoracic echocardiogram is obtained

Answer

The appropriate interventions are to initiate an intravenous dobutamine infusion, discontinue home carvedilol therapy, and discontinue home sacubitril-valsartan therapy.
The correct interventions are initiating an intravenous dobutamine infusion, discontinuing carvedilol, and discontinuing sacubitril-valsartan. This patient is presenting with cardiogenic shock, characterized by severe hypotension, signs of end-organ hypoperfusion (altered mental status, elevated lactate, acute kidney injury), and clinically evident volume overload (pulmonary edema, elevated jugular venous pressure, S3S_3 gallop). Inotropic support, such as dobutamine (a beta-1 agonist), is indicated to augment myocardial contractility and increase cardiac output, thereby restoring tissue perfusion. Simultaneously, negative inotropic agents like carvedilol must be discontinued immediately, as they severely compromise compensatory mechanisms in acute heart failure. Furthermore, sacubitril-valsartan must be held due to the presence of profound hypotension, acute kidney injury, and hyperkalemia; continuing it would further diminish renal perfusion and worsen shock.

Step-by-Step Solution

1
Assess the patient's hemodynamic and volume status based on clinical presentation.
The patient has signs of profound systemic hypoperfusion (hypotension, lactic acidosis, altered mental status, mottled extremities) and volume overload (elevated JVP, pulmonary crackles).
Identifying the specific shock phenotype (cardiogenic shock) is essential for selecting the correct resuscitative pathway.
2
Evaluate the current home medication list against the patient's acute physiologic derangements.
Carvedilol (negative inotrope) and sacubitril-valsartan (vasodilator, nephrotoxin in AKI) are acutely contributing to hypotension and organ hypoperfusion.
Deprescribing harmful medications is a critical pharmacologic intervention in critically ill patients.
3
Select appropriate pharmacologic interventions to restore perfusion and avoid contraindications.
Inotropic support (dobutamine) should be initiated. Intravenous fluids and vasodilators (nitroglycerin) must be avoided.
Dobutamine increases cardiac output, whereas fluids worsen pulmonary edema and vasodilators worsen shock.

Key Concept

Management of cardiogenic shock involves providing immediate inotropic support while simultaneously holding negative inotropes (beta-blockers) and therapies that exacerbate hypotension or acute kidney injury (renin-angiotensin system inhibitors).
Estimated Time:2m 0s
Rate this question

Topics

Pharmacologic Interventions

More questions from this topic